Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease.

ABSTRACT:

Background

Type 2 diabetes (T2D) is the leading cause of chronic kidney disease (CKD) and kidney failure globally. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, reduces the risk of major kidney, cardiovascular and mortality outcomes in people with T2D and CKD, but the mechanism of action remains unclear.

Methods

The REMODEL trial (NCT04865770) is a 52-week placebo-controlled, double-blind, parallel-group, randomized trial in adults with T2D and CKD. Inclusion criteria include haemoglobin A1c (HbA1c) ≤9%, estimated glomerular filtration rate (eGFR) ≥30-≤75 ml/min/1.73 m2 and urine albumin:creatinine ratio (UACR) ≥20-<5000 mg/g. The co-primary outcomes were magnetic resonance imaging (MRI) based, including change in kidney oxygenation, perfusion and inflamma

SUBMITTER: Cherney DZI 

PROVIDER: S-EPMC12559791 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature